Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks

CagriSema Mechanism Explainer

Why combining a long-acting amylin analogue with a GLP-1 agonist may produce more weight reduction than the GLP-1 agonist alone — and what the phase-3 evidence actually shows.

Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.

What CagriSema is

CagriSema is a Novo Nordisk combination of semaglutide and cagrilintide that has been tested in phase 3 trials. In REDEFINE 5 (PMID 42009015) and REIMAGINE 1 (PMID 42251860) it was given as once-weekly subcutaneous injections, and REDEFINE 5 describes it as a fixed-dose combination. On 6 November 2026, searching DailyMed for “cagrilintide” and for “cagrisema”, and the openFDA drug label database for “cagrilintide”, returned no label.

  • Semaglutide — a GLP-1 receptor agonist. An MHRA page (updated 5 February 2026) lists it among licensed GLP-1 medicines sold as Wegovy, Ozempic and Rybelsus; the quotation is under UK regulatory context below. See our semaglutide monograph.
  • Cagrilintide — a long-acting analogue of amylin, the pancreatic hormone co-secreted with insulin. It has been tested alone in a phase 2 dose-finding trial (PMID 34798060) and in combination with semaglutide in the trials below. See our cagrilintide monograph.

REDEFINE 1 (PMID 40544433) and REDEFINE 5 gave cagrilintide 2.4 mg with semaglutide 2.4 mg for 68 weeks, and REIMAGINE 1 gave 2.4 mg or 1.0 mg of each for 40 weeks, all once weekly. The earlier phase 1b trial combined cagrilintide 0.16 to 4.5 mg with semaglutide 2.4 mg.

Why combine two peptides?

A 2026 narrative review says amylin “slows gastric emptying, suppresses glucagon secretion, and promotes meal termination through central mechanisms”, and describes amylin-based therapies as targeting appetite through “pathways different from those used by current glucagon-like peptide-1 (GLP-1) based treatments” (Alhazmi 2026, PMID 42452898). A second 2026 review says amylin-based agents including CagriSema “enhance satiety and glycemic outcomes through complementary actions” (Son 2026, PMID 41054801). These are the reviews’ descriptions of the rationale, not results from a trial designed to test it.

Two pathways, two drugs

Amylin acts through receptors built from the calcitonin receptor paired with one of three receptor-activity-modifying proteins (RAMPs) (Fairweather 2026, PMID 41991490). GLP-1, among other peptide hormones, feeds into appetite circuits that a 2026 scoping review centres on the hypothalamic arcuate nucleus (Abdollahi 2026, PMID 42515672).

In the phase 1b trial (Enebo 2021, Lancet, PMID 33894838; 95 adults exposed to treatment), cagrilintide had a half-life of 159-195 hours and semaglutide 2.4 mg a half-life of 145-165 hours. The abstract also reports that cagrilintide exposure was proportional to dose and did not affect semaglutide exposure or elimination.

Additive or synergistic?

In REDEFINE 1 (PMID 40544433; 3,417 adults without diabetes, 68 weeks) mean body-weight change was -20.4% with cagrilintide-semaglutide (2.4 mg of each, once weekly) against -3.0% with placebo, a difference of -17.3 percentage points. The trial also had semaglutide-alone and cagrilintide-alone arms of 302 participants each; the published abstract gives no result for the combination against either of them. REDEFINE 5 (PMID 42009015; 331 adults in Japan and Taiwan, 68 weeks) compared the combination with semaglutide alone: -18.4% against -11.9%, a difference of -6.5 percentage points (95% CI -8.4 to -4.6). A combination-versus-placebo result cannot show whether the combined effect is additive, more than additive or less than additive, so calling it synergistic goes beyond what these trials show. See our page on why synergy is often assumed, not demonstrated.

Evidence base at a glance

  • Enebo 2021 (Lancet), phase 1b(PMID 33894838) — safety, pharmacokinetics and body weight with cagrilintide plus semaglutide 2.4 mg, in 95 adults exposed to treatment.
  • REDEFINE 1 (Garvey 2025, NEJM), phase 3(PMID 40544433) — obesity without T2D, 68 weeks, combination vs placebo (the abstract reports only that comparison). Gastrointestinal adverse events affected 79.6% of the combination group and 39.9% of the placebo group.
  • REDEFINE 5 (Yamauchi 2026, Lancet Diabetes Endocrinol), phase 3a (PMID 42009015) — 331 adults in Japan and Taiwan, 68 weeks, combination vs semaglutide. Adverse events were reported by 143 of 164 (87%) on the combination and 141 of 167 (84%) on semaglutide; one death was reported in the semaglutide group and was not judged treatment related by the investigator.
  • REDEFINE 2 (Davies 2025, NEJM), phase 3(PMID 40544432) — obesity with T2D, 1,206 adults, 68 weeks, combination vs placebo: -13.7% against -3.4% body weight. Gastrointestinal adverse events were reported by 72.5% of the combination group and 34.4% of the placebo group.
  • REDEFINE 1 blood-pressure analysis (Verma 2026, Hypertension) (PMID 41328546) — secondary and post hoc analyses of blood-pressure change in the combination and placebo groups.
  • REIMAGINE 1 (Aroda 2026, Lancet Diabetes Endocrinol) (PMID 42251860) — T2D inadequately controlled on diet and exercise, 189 adults, 40 weeks, combination vs placebo. Adverse events were reported by 79% (2.4 mg each) and 75% (1.0 mg each) of the combination groups and 66% of the placebo group.
  • REIMAGINE 2 (Buse 2026, Lancet Diabetes Endocrinol) (PMID 42251859) — T2D on metformin, 2,713 adults, 68 weeks, combination vs semaglutide, cagrilintide or placebo. PubMed lists an erratum (PMID 42320507) whose text was not available, so the enrolment figure may differ from the corrected paper.
  • REIMAGINE 3 (Rosenstock 2026, Lancet)(PMID 42251856) — T2D on basal insulin, 274 adults, 40 weeks, combination vs placebo. Adverse events were reported by 80% (2.4 mg each) and 71% (1.0 mg each) of the combination groups and 71% of the placebo group; one death, from malignancy and not related to treatment, was reported in the 1.0 mg group.

Each abstract above except the blood-pressure analysis names Novo Nordisk as funder.

Full citations on the cagrilintide monograph and the CagriSema stack review.

What the evidence does not (yet) show

  • Cardiovascular outcomes. REDEFINE 3, a trial in 7,076 adults with established cardiovascular disease (PMID 42838477), was listed on ClinicalTrials.gov (NCT05669755) on 6 November 2026 as active, not recruiting, with no results posted.
  • Anything beyond 68 weeks: the longest trials cited here with published results ran for 68 weeks; REDEFINE 3 is still running and has no results.
  • Weight after stopping treatment. A 2026 scoping review of appetite-regulating peptide therapies lists “treatment durability, adverse effects, and weight regain following discontinuation” as challenges (Abdollahi 2026, PMID 42515672). The trial abstracts above do not report weight after treatment stopped.

UK regulatory context

This site gives no legal advice or sourcing information and does not sell anything. Rules on unauthorised medicines exist in the Human Medicines Regulations 2012. Whether a particular product is a medicinal product under regulation 2 depends on its specifics, including how it is presented and how it functions. For questions about medicines speak to a GP or pharmacist; problems with a medicine can be reported to the MHRA through the Yellow Card scheme.

The MHRA states: “In the UK, there are several licensed GLP-1 medicines including semaglutide (sold under the brand names Wegovy, Ozempic and Rybelsus), tirzepatide (Mounjaro) and liraglutide (sold under various brand names).” (MHRA, GOV.UK, page updated 5 February 2026).

A search for “cagrilintide” on the electronic medicines compendium (eMC) on 6 November 2026 returned “No search results”; the search covered the eMC only. See also the regulation pages and the weight-loss medicine advertising caution.

Related pages

Published: 2026-06-20Last updated: 2026-11-06

If you spot an error or have new evidence to suggest, please use our corrections policy.